

November 12, 1964

Daniel H. Efron, M.D., Ph.D.
Program Director in Pharmacology
Psychopharmacology Service Center
National Institute of Mental Health
Bethesda, Maryland 20014

Dear Dr. Efron:

My associates and I want to thank you for sending us the references in regard to Synhexyl. Sam Gershon and I have read these and concluded that the data is insufficient to determine whether the compound may have any psychotropic activity, and certainly does not permit us to select target populations or target symptoms for clinical studies.

We believe that preclinical studies using some of the dog screen models suggested by Dr. Gershon are a necessary step. Depending on the results of those investigations some clinical explorations should be made, particularly with reference to our EEG screen model. It is only after these, that a clinical evaluation should be undertaken.

As you know, our funds available for preclinical and clinical screening are severely limited.

We would be pleased to undertake these studies if funds could be made available for both preclinical and some exploratory clinical studies.

Sincerely yours,

Max Fink, M.D.
Director

mf/ls